Comparative Study of Dual Therapy vs Triple Therapy in Severe COPD Management
DOI:
https://doi.org/10.70749/ijbr.v3i2.723Keywords:
COPD, Dual Therapy, Triple Therapy, Exacerbation Rates, Lung Function, Quality of LifeAbstract
Introduction: Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality globally. The management of severe COPD typically involves pharmacological therapies aimed at symptom relief and disease progression slowing. Objective: To assess the effectiveness and safety of dual therapy compared to triple therapy in patients with severe COPD, focusing on exacerbation rates, lung function improvement, and quality of life over 12 months. Methodology: This prospective cohort study was conducted at Sheikh Zayed Teaching Hospital Rahim Yar Khan during 1st July 2024 to 31st December 2024, involving 230 patients with severe COPD, aged 40-80 years, who were recruited from outpatient clinics. These patients were randomly assigned to one of two groups: the dual therapy group (LABA + ICS) and the triple therapy group (LABA + ICS + LAMA). Results: The triple therapy group showed a significant reduction in exacerbation rates (40%) compared to the dual therapy group (25%). Lung function improved significantly in both groups, with a greater improvement observed in the triple therapy group (mean FEV1 increase of 200 mL compared to 150 mL in the dual therapy group). Quality of life, as measured by the CAT score, improved more significantly in the triple therapy group (mean reduction of 6 points) compared to the dual therapy group (mean reduction of 4 points). Conclusion: Triple therapy was found to be more effective in reducing exacerbation rates and improving lung function and quality of life compared to dual therapy in patients with severe COPD.
Downloads
References
Lai, C., Chen, C., Lin, C. Y., Wang, C., & Wang, Y. (2019). The effects of single inhaler triple therapy vs single inhaler dual therapy or separate triple therapy for the management of chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized controlled trials. International Journal of Chronic Obstructive Pulmonary Disease, 14, 1539-1548. https://doi.org/10.2147/copd.s200846
Zhang, S., Wang, J., Li, X., & Zhang, H. (2024). Comparative effectiveness and safety of triple therapy and non-triple therapy interventions for COPD: An overview of systematic reviews". https://doi.org/10.1177/17534666241259634/v3/response1
Zheng, Y., Zhu, J., Liu, Y., Lai, W., Lin, C., Qiu, K., Wu, J., & Yao, W. (2018). Triple therapy in the management of chronic obstructive pulmonary disease: Systematic review and meta-analysis. BMJ, k4388. https://doi.org/10.1136/bmj.k4388
Suissa, S., Dell'Aniello, S., & Ernst, P. (2022). Single-inhaler triple versus dual Bronchodilator therapy in COPD: Real-world comparative effectiveness and safety. International Journal of Chronic Obstructive Pulmonary Disease, 17, 1975-1986. https://doi.org/10.2147/copd.s378486
Suissa, S., Dell'Aniello, S., & Ernst, P. (2022). Single-inhaler triple versus dual Bronchodilator therapy in COPD: Real-world comparative effectiveness and safety. International Journal of Chronic Obstructive Pulmonary Disease, 17, 1975-1986. https://doi.org/10.2147/copd.s378486
Voorham, J., Corradi, M., Papi, A., Vogelmeier, C. F., Singh, D., Fabbri, L. M., Kerkhof, M., Kocks, J. H., Carter, V., & Price, D. (2019). Comparative effectiveness of triple therapyversusdual bronchodilation in COPD. ERJ Open Research, 5(3), 00106-2019. https://doi.org/10.1183/23120541.00106-2019
Mammen, M. J., Lloyd, D. R., Kumar, S., Ahmed, A. S., Pai, V., Kunadharaju, R., Gupta, S., Nici, L., Aaron, S. D., & Alexander, P. E. (2020). Triple therapy versus dual or monotherapy with long-acting Bronchodilators for chronic obstructive pulmonary disease. A systematic review and meta-analysis. Annals of the American Thoracic Society, 17(10), 1308-1318. https://doi.org/10.1513/annalsats.202001-023oc
Lopez-Campos, J. L., Carrasco-Hernandez, L., Quintana-Gallego, E., Calero-Acuña, C., Márquez-Martín, E., Ortega-Ruiz, F., & Soriano, J. B. (2019). Triple therapy for COPD: A crude analysis from a systematic review of the evidence. Therapeutic Advances in Respiratory Disease, 13. https://doi.org/10.1177/1753466619885522
Calzetta, L., Matera, M. G., Rogliani, P., & Cazzola, M. (2020). The role of triple therapy in the management of COPD. Expert Review of Clinical Pharmacology, 13(8), 865-874. https://doi.org/10.1080/17512433.2020.1787830
Sharma, G. N., Ali, S. A., Shrivastav, B., & Mohd, A. N. (2020). Three-drug therapy versus two-drug therapy for management of patient-reported manifestations and quality of life in chronic obstructive pulmonary disease patients: a meta-analysis. Journal of Applied Pharmaceutical Science, 10(10), 036-049. https://japsonline.com/admin/php/uploads/3216_pdf.pdf
Lipson, D. A., Barnhart, F., Brealey, N., Brooks, J., Criner, G. J., Day, N. C., Dransfield, M. T., Halpin, D. M., Han, M. K., Jones, C. E., Kilbride, S., Lange, P., Lomas, D. A., Martinez, F. J., Singh, D., Tabberer, M., Wise, R. A., & Pascoe, S. J. (2018). Once-daily single-inhaler triple versus dual therapy in patients with COPD. New England Journal of Medicine, 378(18), 1671-1680. https://doi.org/10.1056/nejmoa1713901
Lai, C., Chen, C., Chen, K., Wang, C., Huang, T., Wang, Y., & Wang, H. (2022). The impact of 52-Week single inhaler device triple therapy versus dual therapy on the mortality of COPD patients: A systematic review and meta-analysis of randomized controlled trials. Life, 12(2), 173. https://doi.org/10.3390/life12020173
Buhl, R., Criée, C., Kardos, P., Vogelmeier, C., Kostikas, K., Lossi, N. S., & Worth, H. (2018). Dual bronchodilation vs triple therapy in the “real-life” COPD DACCORD study. International Journal of Chronic Obstructive Pulmonary Disease, 13, 2557-2568. https://doi.org/10.2147/copd.s169958
Additional Files
Published
Issue
Section
License
Copyright (c) 2025 Indus Journal of Bioscience Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
